Increased plasma lipoprotein(a) in continuous ambulatory peritoneal dialysis is related to peritoneal transport of proteins and glucose

Nephron

Volumn 72, Issue 2, 1996, Pages 135-144

  Heimbürger, Olof ^a   Stenvinkel, Peter ^a   Berglund, Lars ^b,c   Tranceus, Anders ^a   Lindholm, Bengt ^a  

^a Departments of Renal Medicine   (United States)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c The New York Presbyterian Hospital   (United States)

Author keywords

Glucose absorption; Hemodialysis; Hyperlipidemia; Lipoprotein(a); Peritoneal dialysis; Peritoneal protein loss; Peritoneal transport

Indexed keywords

ALBUMIN; BETA 2 MICROGLOBULIN; CHOLESTEROL; GLUCOSE; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROTEIN;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED STUDY; FEMALE; GLUCOSE ABSORPTION; HEMODIALYSIS; HUMAN; LIPOPROTEIN BLOOD LEVEL; LONGITUDINAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN DEPLETION; UREMIA;

ADULT; AGED; AGED, 80 AND OVER; ALBUMINS; BETA 2-MICROGLOBULIN; BIOLOGICAL TRANSPORT; CHOLESTEROL; CROSS-SECTIONAL STUDIES; DIETARY PROTEINS; ENERGY INTAKE; FEMALE; GLUCOSE; HUMANS; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; LIPIDS; LIPOPROTEIN(A); LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; PERITONEUM; RENAL DIALYSIS; UREMIA;

EID: 0030032429     PISSN: 16608151     EISSN: 22353186     Source Type: Journal    
DOI: 10.1159/000188831     Document Type: Article

References (69)

1. Berg K: A new serum type system in man-The Lp svstem. Acta Pathol Microbiol Scand 1963; 59:369-382.
2. Utcrmann G: The mysteries of lipoprotein (a). Science 1989;246:904-910.
3. Boerwinkle E. Leffert CC, Lin J, Lackner C, Chiesa G, Hobbs HH: Apolipoprotein (a) gene accounts for greater than 90% of the variation in plasma lipoprotein (a) concentrations. J Clin Invest 1992;90:52-60.
4. Kremplcr F. Kostner GM. Roscher A. Haslau-ser F, Bolzano K, Sandhofer F: Studies on the role of specific cell surface receptors in the removal of lipoprotein (a) in man. J Clin Invest 1983;71:1431-1441.
5. Scanu AM: Lipoprotein (a), a genetic risk factor for premature coronary heart disease. JAMA 1992;267:3326-3329.
6. Dahlcn GH, Guyton JR, Attar M, Farmer JA, Kautz JA, Gotto AM: Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation 1986;74: 758-765.
7. Armstrong VW, Cremer P, Eberle E, Manke A, Schultzc F, Wieland H, Kreutzer K, Seidel D: The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis: Dependence on serum LDL levels. Atherosclerosis 1986:62:249-257.
8. Scott J: Trombogenesis linked to atherogencsis at last. Nature 1989:339:301-303.
9. Haffner SM: Lipoprotein (a) and diabetes. Diabetes Care 1993;16:835-840.
10. Karadi I. Romics L, Palos G. Doman J. Kaszas I, Hesz A, Kostner GM: Lp(a) lipoprotein concentration in scrum of patients with heavy proteinuria. Clin Chem 1989:35:109-113.
11. Thomas ME, Freestone A, Varghese Z, Persaud JW, Moorhead JF: Lipoprotein (a) in patients with proteinuria. Nephrol Dial Transplant 1992;7:597-601.
12. Stenvinkel P. Berglund L. Heimbürger O, Pet-tersson E, Alvcstrand A: Lipoprotein (a) in nephrotic syndrome. Kidney Int 1993:44: 1116-1123.
13. Cressman MD, Hoft HF, Nally JV Jr. Schreiber M Jr, Van Lente F: Lipoprotein (a) and the cardiovascular risk of endstage renal disease (abstract). J Am Soc Nephrol 1991:2:234.
14. Murphy BG, McNamee P, Duly E, Henry W, Archbold P, Trinick T: Increased serum apolipoprotein (a) in patients with chronic renal failure treated with continuous ambulatory peritoneal dialysis. Atherosclerosis 1992;93:53-57.
15. Haffner SM, Gruber KK, Aldrcte G, Morales PA. Stern MP, Tuttle KR: Increased lipoprotein (a) concentrations in chronic renal failure. J Am Soc Nephrol 1992;3:1156-1162.
16. Ross EA. Shah GM. Gupta AK, Kashyap ML: Elevated lipoprotein (a) in peritoneal dialysis patients (abstract). J Am Soc Nephrol 1992;3: 418.
17. Irish AB. Simons LA, Savdie E, Hayes JM. Simons J: Lipoprotein (a) levels in chronic renal disease states, dialysis and transplantation. Aust NZ J Med 1992;22:243-248.
18. Schrciber MJ, Crcssman MD, Coscntio F. Van Lcntc F: Lipoprotein (a) and peritoneal dialysis (abstract). Peril Dial Int 1992; 12:S157.
19. Shoji T. Nishizawa Y. Nishitani H. Yamakawa M, Morii H: High serum lipoprotein (a) concentrations in uremic patients treated with continuous ambulatory peritoneal dialysis. Clin Nephrol 1992;38:271-276.
20. Webb AT. Reaveley DA, O'Donnell M. O'Connor B, Seed M. Brown EA: Lipoprotein (a) in patients on maintenance haemodialysis and continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 1993:8:609-613.
21. Stegmavr BG. Korosh T: Increased lipoprotein (a) in patients on CAPD (abstract). Perit Dial Int 1993; 13:S71.
22. Anwar N, Bhatnagar D. Short CD, Mackness MI. Durrington PN. Prais H, Gokal R: Serum lipoprotein (a) concentrations in patients undergoing continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 1993:8:71-74.
23. Thillet J, Faucher C. Issad B. Allouache M. Chapman J, Jacobs C: Lipoprotein(a) in patients treated by continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1993:22:226-232.
24. Barbagallo CM, Avcma MR, Sparacino V, Ga-lione A, Caputo F. Scaftdi V, Amato S. Manci-no C. Cefalu AB, Notarbartolo A: Lipoprotein (a) levels in end-stage renal failure and renal transplantation. Nephron 1993:64:560-564.
25. Siakotos M. Apostolou T, Papgeorgakis N. Ma-taxatos G, Melpidou A, Nikolopoulou N, Anagnostou E, Billis A: Serum Lp(a) lipoprotein concentration in patients with chronic renal failure (abstract). Perit Dial Int 1992: 12(suppl 2):S46.
26. Buggu D. Breathnach A, Keogh B, Cooke T. Feely J: Lipoprotcin(a) and treatment of chronic renal disease. J Intern Med 1993,234: 453-455.
27. Kandoussi A, Cachera C. Paginez D, Dracon M, Fruchart JC. Tacquet A: Plasma level of lipoprotein Lp(a) is high in predialysis or hemodialysis. but not in CAPD. Kidney Int 1992; 42: 424-425.
28. Parra HJ. Mezdour H, Cachera C, Dracon M, Tacquet A. Fruchart JC: Lp(a) lipoprotein in patients with chronic renal failure treated by hemodialysis. Clin Chem 1987:33:721.
29. Parsy D, Dracon M. Cachera C, Parra H-J, Vanhoutte G. Tacquet A. Fruchart J-C: Lipoprotein abnormalities in chronic haemodialysis patients. Nephrol Dial Transplant 1988:3:51-56.
30. Nakahama H. Miyazaki M. Imai N, Yokokawa T, Okada M. Kubori S. Okamural K, Tanaka Y. Shirai D: Reduction of plasma lipoprotei-n(a) levels by niceritro! in patients on maintenance hemodialysis(abstract). J Am Soc Nephrol 1991:2:340.
31. Cressman MD, Heyka RJ. Paganini EP, O'Neil J, Skibinski CI, Hoff HF: Lipoprotcin(a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation 1992;86:475-482.
32. Heimann P. Josephson MA. Fellner SK. Thist-lethwaitc JR Jr, Stuart FP. Dasgupta A: Elevated lipoprotcin(a) levels in renal transplantation and hemodialysis patients. Am J Nephrol 1991:11:470-474.
33. Massy ZA. Lacour B. Chaveneau P. Zingraff J. Lambrey G. Driiekc T. Bader A, Jungers P: Serum lipoprotein(a) in patients (Pts) with different degrees of chronic renal failure (CRF) before and after initiation of dialysis therapy (abstract). J Am Soc Nephrol 1992,3:378.
34. Modi KS, Ma JZ. Kasiske BL. Collins AJ. Keane WF: Lipoprotein-A (Lp(a)) in hemodialysis (HD) patients (abstract). J Am Soc Nephrol 1992:3:380.
35. Barbagallo CM. Avcma MR. Scafidi V, Ga-lione A. Notarbartolo A: Increased lipopro-tein(a) levels in subjects with chronic renal failure on hemodialysis. Nephron 1992:62:471-472.
36. Okura Y. Saku K. Hirata K. Zhang B. Liu R. Oguhara S, Naito S. Kajiyama G. Arakawa K: Serum lipoprotein(a) levels in maintenance hemodialysis patients. Nephron 1993:65:46-50.
37. Hirata K. Kikuchi S. Saku K, Jimi S. Zhang B. Naito S. Hamaguchi H. Arakawa K: Apolipo-protein(a) phenotypes and serum lipoprotei-n(a) levels in maintenance hemodialysis patients with/without diabetes mellitus. Kidney Int 1993:44:1062-1070.
38. Auguet T, Senti M, Rubiés-Prat J, Pelegri A. Pedro-Botet J, Nogués X. Romero R: Serum lipoprotcin(a) concentration in patients with chronic renal failure receiving haemodialysis: Influence of apoprotein (a) genetic polymorphism. Nephrol Dial Transplant 1993:8:1099-1103.
39. Jurgens G, Chen Q, Meinitzer A, Petek W: Lipoprotein(a): Its atherogcnicity, structure, and quantification. Lab Med Int 1994:11:7-9.
40. Webb A, Plant M. Reaveley DA, O'Donnell M, Luck VA, O'Connor B, Seed M. Brown EA: Lipid and lipoprotein(a) concentration in renal transplant patients. Nephrol Dial Transplant 1992;7:636-641.
41. Black IW, Wilcken DEL: Decrease in apolipo-protein (a) after renal transplantation: Implication for lipoprotein (a) metabolism. Clin Chem 1992:38:353-357.
42. Heimbiirger O, Waniewski J, Wcrynski A, Lindholm B: A quantitative description of solute and fluid transport during peritoneal dialysis. Kidney Int 1992;41:1320-1332.
43. Lopes-Virella MF, Stone P. Ellis S. Colwell JA: Cholesterol determination in high-density lipoprotein separated by three different methods. Clin Chem 1977:23:882-884.
44. Friedewald WT. Levy Rl. Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultraccntrifugc. Clin Chem 1977:18:499-502.
45. Twardowski ZJ. Nolph KD. Khanna R, Prowant BF, Ryan LP. Moore HL. Nielsen MP: Peritoneal equilibration test. Perit Dial Bull 1987;7:138-147.
46. Bergstrom J. Fiirst P, Alvestrand A. Lindholm B: Protein and energy intake, nitrogen balance and nitrogen losses in patients treated with continuous ambulatory peritoneal dialysis. Kidney Int 1993;44:1048-1057.
47. Yang WS, Kim SB. Min WK, Park S, Hong CD, Park JS: Inverse relationship between serum lipoprotein(a) and albumin concentration in hemodialysis patients (abstract). Abstract book of the 31st Congress of the EDTA-ERA, Vienna, 1994.
48. Yamamuchi A, Yamamoto S, Fukuhara Y, Orita Y. Kamada T, Noguchi T, Tanaka T: Oncotic pressure regulates the levels of albumin (Alb) mRNA and apolipoprotein B (ApoB) in cultured rat hepatoma cells (H4IIE) (abstract). Kidney Int 1989;35:441A.
49. Pullinger CR, North JD. Teng BB. Rifici VA, Ronhild de Brito AE. Scott J: The apolipoprotein B gene is constitutively expressed in HcpG2 cells: Regulation of secretion by oleic acid, albumin, and insulin, and measurement of the mRNA half-life. J Lipid Res 1989:30: 1065-1077.
50. Kaysen GA, Schoenfeld PY: Albumin homeostasis in patients undergoing continuous ambulatory peritoneal dialysis. Kidney Int 1984;25: 107-114.
51. Bonomini V, Zuccheli P, Mioli V: Selective and unselcctive protein loss in peritoneal dialysis. in Kerr DNS (ed): Proc EDTA IV. Paris, Excerpta Medica Foundation. 1967. vol 4. pp 146-149.
52. Rothschild MA, Oratz M. Evans CD. Schreibcr SS: Role of hepatic interstitial albumin in regulating albumin synthesis. Am J Physiol 1966; 210:57-68.
53. Oratz M: Oncotic pressure and albumin synthesis: in Bianchi R. Mariani G, MacFarlanc AS (eds): Plasma Protein Turnover. Baltimore. University Park Press. 1976, pp 223-237.
54. Kagan A, Bar-Khavim Y. Schafer Z, Fainaru M: Kinetics of peritoneal protein loss during CAPD. II. Lipoprotein leakage and its impact on plasma lipid levels. Kidney Int 1990:37: 980-990.
55. Prichard S. Cianflone K. Zhang ZJ, Snidcrman A: A novel mechanism to explain the dyslipi-demia in CAPD and nephrotic patients (abstract). Perit Dial Int 1992; 12:S150.
56. Snidcrman AD, Zhang ZJ, Vu H, Kalant C. Cianflone K: Apo B and Lp(a) arc not always constitutively synthesized and secreted in HepG2 cells: Regulatory control by amino acids (abstract). Circulation 1993:88:1-176.
57. Lindholm B, Norbeck HE: Serum lipids and lipoproteins during continuous ambulatory peritoneal dialysis. Acta Med Scand 1986:220: 143-151.
58. Lindholm B, Berstrôm J: Nutritional requirements of peritoneal dialysis; in Gokal R. Nolph KD (eds): Textbook of Peritoneal Dialysis. Dordrecht, Kluwer. Academic, 1994. pp 443-472.
59. Shoji T. Nishizawa Y, Nishitani H, Yamakawa M, Morii H: Roles of hypoalbuminemia and lipoprotein lipase on hyperlipoproteinemia in continuous ambulatory peritoneal dialysis. Metabolism 1991:40:1002-1008.
60. Eden S. Wiklund O, Oscarsson J, Rosén T, Bengtsson B-À; Growth hormone treatment of growth hormone-deficient adults results in a marked increase in Lp(a) and HDL cholesterol concentrations. Arteriosclcr Thromb 1993; 13: 296-301.
61. Olivccrona H. Ericsson S. Berglund L. Angelin B: Increased concentrations of serum lipopro-tein(a) in response to growth hormone treatment. Br Med i 1993:306:1726-1727.
62. Kaysen GA: Albumin metabolism in the nephrotic syndrome: The effect of dietary protein intake. Am J Kidney Dis 1988;25:107-114.
63. Joven J, Villabona C, Vilella E, Masana L. Alterti R, Vallès M: Abnormalities of lipoprotein metabolism in patients with the nephrotic syndrome. N Engl J Med 1990:323:579-584.
64. Attman PO. Alaupovic P: Pathogenesis of hyperlipidemia in the nephrotic syndrome. Am J Nephrol 1990;10(suppl 1):69-75.
65. Warwick GL, Packard CJ: Lipoprotein metabolism in the nephrotic syndrome. Nephrol Dial Transplant 1993:8:385-396.
66. Kaysen GA: Nephrotic hyperlipidemia: Primary abnormalities in both lipoprotein catabolism and synthesis. Miner Electrolyte Metab 1992; 18:212-216.
67. Kaysen GA, Don B, Schambclan M: Proteinuria. albumin synthesis and hyperlipidemia in the nephrotic syndrome. Nephrol Dial Transplant 1991;6:141-149.
68. Kaysen GA, Gambertoglio J. Felts J, Hutchinson FN: Albumin synthesis, albuminuria and hyperlipidemia in the nephrotic patients. Kidney Int 1987:31:1368-1376.
69. Davies RW, Staprans I, Hutchinson FN, Kaysen GA: Proteinuria, not altered albumin metabolism, affects hyperlipidemia in the nephrotic rat. J Clin Invest 1990:86:600-605.